Product Description
SPN-538 (Trokendi XR,Supernus Pharmaceuticals, Inc.) is a novel extended-release, once-daily capsule formulation of TPM that may improve tolerability and adherence.
Mechanisms of Action: Sodium Channel Antagonist
Novel Mechanism: No
Modality: N/A
Route of Administration: N/A
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Supernus
Company Location: ROCKVILLE MD 20850
Company CEO: Jack A. Khattar
Additonal Commercial Interests: None
Clinical Description

Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 4: Headache Disorders|Migraine Disorders
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
538P401 | P4 |
Terminated |
Migraine Disorders|Headache Disorders |
2024-05-29 |